The levels of monocyte chemotactic protein 1 and serum amyloid A protein in peripheral blood and their correlation with cognitive function in COPD patients with or without hypoxemia_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

GE Yanlei , LIU Conghui , ZHANG Jiabin , CUI Ziyang , LI liqun , ZHANG Panpan , TAN Xishu ,  WANG Hongyang

Department of Respiratory Medicine, Affiliated Hospital of North China University of Science and Technology, Tangshan, Hebei 063000, P. R. China;

Corresponding?author：

WANG Hongyang, Email: tsmywhy@163.com

Keywords：

Chronic obstructive pulmonary disease; Cognitive dysfunction; Monocyte chemotactic protein-1; Amyloid A protein; Hypoxemia

DOI：

10.7507/1671-6205.201711033

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the correlation of protein and mRNA levels of monocyte chemotactic protein-1 (MCP-1) and serum amyloid A protein (SAA) with cognitive function in chronic obstructive pulmonary disease (COPD) patients with or without hypoxemia, in order to identify the serum indexes of early cognitive impairment in patients with COPD, and investigate the effect of hypoxemia on cognitive impairment. Methods Sixty-two COPD patients admitted in the respiratory department of Affiliated Hospital of North China University of Science and Technology from January 2013 to January 2017 were included in the study. The COPD patients were divided into a hypoxemia group (25 cases) and a non-hypoxemia group (37 cases) according to blood gas analysis. Meanwhile 30 healthy subjects were recruited as control. ELISA was used to measure the concentration of serum MCP-1 and SAA in all subjects, and RT-PCR was used to detect the mRNA expression of MCP-1 and SAA in peripheral blood mononuclear cells. Montreal cognitive assessment scale (MoCA scale) was used to determine cognitive function. The expression levels of MCP-1 and SAA were compared between three groups, and the correlations with cognitive dysfunction were analyzed. Results The expression levels of serum MCP-1 and SAA had the same trend as those of MCP-1 mRNA and SAA mRNA in peripheral blood in the COPD patients. The protein and mRNA levels of MCP-1 and SAA were higher than those in the healthy control group (all P<0.05). The COPD hypoxemia group and the COPD non-hypoxemia group were lower than the control group in MoCA score, and the MoCA score of the COPD hypoxemia group decreased more obviously (allP<0.05). The protein and mRNA levels of SAA and MCP-1 were negatively correlated with MoCA score (allP<0.05). Conclusion The protein and mRNA levels of MCP-1 and SAA in peripheral blood increase in COPD patients, and hypoxemia may be involved in cognitive dysfunction in COPD patients.

Citation： GE Yanlei, LIU Conghui, ZHANG Jiabin, CUI Ziyang, LI liqun, ZHANG Panpan, TAN Xishu, WANG Hongyang. The levels of monocyte chemotactic protein 1 and serum amyloid A protein in peripheral blood and their correlation with cognitive function in COPD patients with or without hypoxemia. Chinese Journal of Respiratory and Critical Care Medicine, 2018, 17(4): 327-330. doi: 10.7507/1671-6205.201711033 Copy

1.	Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J, 2010, 35(4): 913-922.
2.	Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J, 2009, 33(5): 1165-1185.
3.	Thakur N, Blank PD, Julian LJ, et al. COPD and cognitive impairment: the role of hypoxemia and oxygen therapy. Int J Chron Obstruct Pulmon Dis, 2010, 5: 263-269.
4.	Galimberti D, Schoonenenboom N, Scarpini E, et al. Dutch-Italian Alzheimer Research Group: Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann Neurol, 2003, 53(4): 547-548.
5.	Flenley DC. Sleep in chronic obstructive lung disease. Clin Chest Med, 1985, 6(4): 651-661.
6.	Monzon ME, Forteza RM, Caslino-matsuda SM. MCP-1/CCR2B-dependent loop upregulates MUC5AC and MUC5B in human airway epithelium. Am J Physiol Lung Cell Mol Physiol, 2011, 300(2): L204-L215.
7.	申永春, 文富強, 賀蓓[譯校]. 慢性阻塞性肺疾病全球創議(2011 年修訂版)概述. 中華醫學雜志, 2012, 92(14): 937-938.
8.	Bozinovski S, Hutchinson A, Thompson M, et al. Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2008, 177(3): 269-278.
9.	Lima OM, Oliveira-souzaS R, Santos-oda R, et al. Subclinical encephalopathy in chronic obstructive pulmonary disease. Arq Neuropsiquiatr, 2007, 65(4B): 1154-1157.
10.	Incalzira, Gemma A, Marra C, et al. Verbal memory impairment in COPD: its mechanisms and clinical relevance. Chest, 1997, 112(6): 1506-1513.
11.	李力仙, 戴黎萌. 單核細胞及其趨化因子與腦缺血再灌注損傷. 國外醫學腦血管疾病分冊, 2000, 8(2): 89-91.
12.	Yu Y, Liu J, Li S Q, et al. Serum amyloid a differentially activates microglia and astrocytes via the PI3K pathway. Alzheimers Dis, 2014, 38(1): 133-144.
13.	董哲. 血清淀粉樣蛋白 A 加速動脈粥樣硬化斑塊形成及其致炎作用的機制研究[D]. 山東: 山東大學, 2012.
14.	姚朝輝, 張少鋒, 劉娟. 老年癡呆患者血清胱氨酸蛋白酶抑制劑 C 與認知功能、腦灌注水平的相關性研究. 中華行為醫學與腦科學雜志, 2014, 23(11): 993-996.
15.	Ortapamuk H, Naldoken S. Brain perfusion abnormalities in chronic obstructive pulmonary disease: comparison with cognitive impairment. Ann Nucl Med, 2006, 20(2): 99-106.
16.	Antonelli, Incalzi R, Marra C, et al. Cognitive impairment in chronic obstructive pulmonary disease-a neuropsychological and spect study. Neurol, 2003, 250(3): 325-332.
17.	柴寧, 王嵐, 王學義. 輕度認知功能損害核磁共振研究的進展. 中華行為醫學與腦科學雜志, 2013, 22(4): 383-384.

1. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J, 2010, 35(4): 913-922.
2. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J, 2009, 33(5): 1165-1185.
3. Thakur N, Blank PD, Julian LJ, et al. COPD and cognitive impairment: the role of hypoxemia and oxygen therapy. Int J Chron Obstruct Pulmon Dis, 2010, 5: 263-269.
4. Galimberti D, Schoonenenboom N, Scarpini E, et al. Dutch-Italian Alzheimer Research Group: Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann Neurol, 2003, 53(4): 547-548.
5. Flenley DC. Sleep in chronic obstructive lung disease. Clin Chest Med, 1985, 6(4): 651-661.
6. Monzon ME, Forteza RM, Caslino-matsuda SM. MCP-1/CCR2B-dependent loop upregulates MUC5AC and MUC5B in human airway epithelium. Am J Physiol Lung Cell Mol Physiol, 2011, 300(2): L204-L215.
7. 申永春, 文富強, 賀蓓[譯校]. 慢性阻塞性肺疾病全球創議(2011 年修訂版)概述. 中華醫學雜志, 2012, 92(14): 937-938.
8. Bozinovski S, Hutchinson A, Thompson M, et al. Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2008, 177(3): 269-278.
9. Lima OM, Oliveira-souzaS R, Santos-oda R, et al. Subclinical encephalopathy in chronic obstructive pulmonary disease. Arq Neuropsiquiatr, 2007, 65(4B): 1154-1157.
10. Incalzira, Gemma A, Marra C, et al. Verbal memory impairment in COPD: its mechanisms and clinical relevance. Chest, 1997, 112(6): 1506-1513.
11. 李力仙, 戴黎萌. 單核細胞及其趨化因子與腦缺血再灌注損傷. 國外醫學腦血管疾病分冊, 2000, 8(2): 89-91.
12. Yu Y, Liu J, Li S Q, et al. Serum amyloid a differentially activates microglia and astrocytes via the PI3K pathway. Alzheimers Dis, 2014, 38(1): 133-144.
13. 董哲. 血清淀粉樣蛋白 A 加速動脈粥樣硬化斑塊形成及其致炎作用的機制研究[D]. 山東: 山東大學, 2012.
14. 姚朝輝, 張少鋒, 劉娟. 老年癡呆患者血清胱氨酸蛋白酶抑制劑 C 與認知功能、腦灌注水平的相關性研究. 中華行為醫學與腦科學雜志, 2014, 23(11): 993-996.
15. Ortapamuk H, Naldoken S. Brain perfusion abnormalities in chronic obstructive pulmonary disease: comparison with cognitive impairment. Ann Nucl Med, 2006, 20(2): 99-106.
16. Antonelli, Incalzi R, Marra C, et al. Cognitive impairment in chronic obstructive pulmonary disease-a neuropsychological and spect study. Neurol, 2003, 250(3): 325-332.
17. 柴寧, 王嵐, 王學義. 輕度認知功能損害核磁共振研究的進展. 中華行為醫學與腦科學雜志, 2013, 22(4): 383-384.

Chinese Journal of Respiratory and Critical Care Medicine

The levels of monocyte chemotactic protein 1 and serum amyloid A protein in peripheral blood and their correlation with cognitive function in COPD patients with or without hypoxemia

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content